Condition: Localized Colon Carcinoma · Stage IIB Colon Cancer AJCC v8 · Stage IIC Colon Cancer AJCC v8 · Sponsor: Emory University
This phase II trial tests how well immunotherapy (toripalimab) works for reducing the risk of cancer recurrence after surgery in patients with mismatch repair deficient stage IIB, IIC, or III colon cancer.
This description comes directly from the study's public registry record.
Oluwadunni E. Emiloju, MBBS, MS · 404-778-1900 · oluwadunni.eunice.emiloju@emory.edu
Olatunji B. Alese, MD, FASCO · olatunji.alese@emory.edu
Always discuss trial participation with your own doctor first.
| Emory Decatur Hospital | Atlanta, Georgia, United States | Recruiting |
| Emory University Hospital Midtown | Atlanta, Georgia, United States | Recruiting |
| Emory University Hospital/Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Emory Saint Joseph's Hospital | Atlanta, Georgia, United States | Recruiting |
| Emory Johns Creek Hospital | Johns Creek, Georgia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07140679